ArticleOphthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)2025
Radiometric and safety assessment of a 'low-level red-light' myopia control device.
Article in Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Current Evidence on Options and Efficacy of Combination Therapy for Myopia Control-A Narrative Review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
- Ocular Transmission of Red and Violet Light: Insights into Light-Based Myopia Therapies.Translational vision science & technology · 2026Article
- Pre-Myopic Children: Trends in Myopia Development and Management in Canada.Journal of clinical medicine · 2026Article
- Radiometric and safety assessment of a 'low-level red-light' myopia control device.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Article
- Editorial: Diagnostic and therapeutic applications of visible and near-infrared light for the retina.Frontiers in ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeRecent literature has demonstrated that 'low-level red-light therapy' may be effective at slowing axial elongation in children, but reports have questioned the safety of some red-light devices. The current work explored the beam characteristics and hazard potential for a myopia control red-light device.
methodsThe optical design and exiting beam characteristics of a sample red-light myopia control device (SECONEE sky-n1201a) were quantified by measuring beam divergence and total flux passing through artificial pupils of 1-9 mm diameter placed at the corneal plane. Retinal exposure levels were compared to American National Standards Institute (ANSI) limits for ophthalmic instruments (Z80.36-2021).
resultsTwo 655 nm laser diodes created exiting red-light beams (~9 mm in diameter) that were approximately collimated by an internal pair of +10.00 D eye-piece lenses resulting in exit vergences ranging from -3.25 to -7.75 D as interpupillary distance settings were adjusted from 52 to 70 mm. Radiant power (mW) passing through the artificial pupils increased from 0.005 to 0.65 mW as pupil diameters increased from 1 to 9 mm. Using ANSI Z80.36-2021, time-averaged retinal radiant exposures (J/cm
conclusionsThe optical design and resulting beam characteristics of this sample red-light myopia control device generate retinal exposure levels that vary with pupil diameter, accommodation and eye movements. Conservative estimates reveal retinal radiant exposures that can exceed ANSI safety limits. The 'low-level' moniker is inappropriate for a device that either exceeds or is just below the ANSI threshold for potential retinal hazard.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.